Table 1 Correlation of clinicopathological characteristics with and prognostic assessment of CD40 expression, divided into low CD40 expression and high CD40 expression categories by median. (OS, overall survival)

Age

67 [43, 89]

69 [43, 84]

0.17

62 [17, 85]

65 [34, 91]

0.41

71 [46, 87]

70 [34, 86]

0.6

Gender

0.89

n/a

0.31

 Female

67 (63%)

65 (61%)

50 (100%)

50 (100%)

33 (48%)

39 (57%)

 Male

40 (37%)

42 (39%)

n/a

n/a

36 (52%)

29 (43%)

Race

 > 0.99

0.24

0.76

 White

99 (93%)

98 (92%)

50 (100%)

47 (94%)

64 (93%)

62 (91%)

 Non-white

8 (7%)

9 (8%)

0 (0%)

3 (6%)

5 (7%)

6 (9%)

Smoking (current/former)

0.16

n/a

 > 0.99

 Yes

97 (91%)

89 (83%)

n/a

n/a

40 (58%)

42 (62%)

 No

10 (9%)

18 (17%)

n/a

n/a

26 (38%)

26 (38%)

 Unknown

n/a

n/a

3 (4%)

0 (0%)

Stage

0.96

0.48

0.39

 I

73 (68%)

74 (69%)

13 (26%)

10 (20%)

5 (7%)

1 (1%)

 II

26 (24%)

26 (24%)

3 (6%)

6 (12%)

62 (90%)

64 (94%)

 III

8 (7%)

7 (7%)

33 (66%)

31 (62%)

1 (1%)

2 (3%)

 IV

n/a

n/a

1 (2%)

3 (6%)

1 (1%)

1 (1%)

Histology

0.18

0.16

 > 0.99

 Squamous (NSCLC only)

24 (22%)

33 (31%)

n/a

n/a

n/a

n/a

 Adenocarcinoma

80 (75%)

68 (64%)

9 (18%)

10 (20%)

68 (99%)

67 (99%)

 Serous (ovarian cancer only)

n/a

n/a

18 (36%)

26 (52%)

n/a

n/a

 Other

3 (3%)

6 (6%)

23 (46%)

14 (28%)

1 (1%)

1 (1%)

OS (months)

49 [0.3, 96]

50 [0.2, 95]

0.27

27 [3, 153]

42 [2, 346]

0.25

22 [4, 95]

37 [1.3, 107]

0.47